ID   APOC3_HUMAN             Reviewed;          99 AA.
AC   P02656; Q08E83; Q6Q786;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   10-MAY-2017, entry version 172.
DE   RecName: Full=Apolipoprotein C-III;
DE            Short=Apo-CIII;
DE            Short=ApoC-III;
DE   AltName: Full=Apolipoprotein C3;
DE   Flags: Precursor;
GN   Name=APOC3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=6439535; DOI=10.1089/dna.1.1984.3.449;
RA   Protter A.A., Levy-Wilson B., Miller J., Bencen G., White T.,
RA   Seilhamer J.J.;
RT   "Isolation and sequence analysis of the human apolipoprotein CIII gene
RT   and the intergenic region between the apo AI and apo CIII genes.";
RL   DNA 3:449-456(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6548954; DOI=10.1089/dna.1984.3.359;
RA   Levy-Wilson B., Appleby V., Protter A.A., Auperin D., Seilhamer J.J.;
RT   "Isolation and DNA sequence of full-length cDNA for human
RT   preapolipoprotein CIII.";
RL   DNA 3:359-364(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=2989400;
RA   Karathanasis S.K., Zannis V.I., Breslow J.L.;
RT   "Isolation and characterization of cDNA clones corresponding to two
RT   different human apoC-III alleles.";
RL   J. Lipid Res. 26:451-456(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=6328445; DOI=10.1093/nar/12.9.3917;
RA   Sharpe C.R., Sidoli A., Shelley C.S., Lucero M.A., Shoulders C.C.,
RA   Baralle F.E.;
RT   "Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA
RT   abundance.";
RL   Nucleic Acids Res. 12:3917-3932(1984).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15108119; DOI=10.1007/s00439-004-1106-x;
RA   Fullerton S.M., Buchanan A.V., Sonpar V.A., Taylor S.L., Smith J.D.,
RA   Carlson C.S., Salomaa V., Stengaard J.H., Boerwinkle E., Clark A.G.,
RA   Nickerson D.A., Weiss K.M.;
RT   "The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.";
RL   Hum. Genet. 115:36-56(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas, and Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 21-99.
RX   PubMed=3949020; DOI=10.1016/0014-5793(86)80300-3;
RA   Hospattankar A.V., Brewer H.B. Jr., Ronan R., Fairwell T.;
RT   "Amino acid sequence of human plasma apolipoprotein C-III from
RT   normolipidemic subjects.";
RL   FEBS Lett. 197:67-73(1986).
RN   [8]
RP   PROTEIN SEQUENCE OF 21-99.
RX   PubMed=4846755;
RA   Brewer H.B. Jr., Shulman R., Herbert P., Ronan R., Wehrly K.;
RT   "The complete amino acid sequence of alanine apolipoprotein (apoC-3),
RT   and apolipoprotein from human plasma very low density lipoproteins.";
RL   J. Biol. Chem. 249:4975-4984(1974).
RN   [9]
RP   REVIEW.
RX   PubMed=18201179; DOI=10.1111/j.1742-1241.2007.01678.x;
RA   Chan D.C., Chen M.M., Ooi E.M., Watts G.F.;
RT   "An ABC of apolipoprotein C-III: a clinically useful new
RT   cardiovascular risk factor?";
RL   Int. J. Clin. Pract. 62:799-809(2008).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT THR-94, AND STRUCTURE OF
RP   CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   REVIEW.
RX   PubMed=22510806; DOI=10.1097/MOL.0b013e328352dc70;
RA   Yao Z., Wang Y.;
RT   "Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein
RT   production.";
RL   Curr. Opin. Lipidol. 23:206-212(2012).
RN   [13]
RP   GLYCOSYLATION AT THR-94, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23527852; DOI=10.1021/pr400136p;
RA   Nicolardi S., van der Burgt Y.E., Dragan I., Hensbergen P.J.,
RA   Deelder A.M.;
RT   "Identification of new apolipoprotein-CIII glycoforms with ultrahigh
RT   resolution MALDI-FTICR mass spectrometry of human sera.";
RL   J. Proteome Res. 12:2260-2268(2013).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   STRUCTURE BY NMR IN COMPLEX WITH SDS MICELLES, AND FUNCTION.
RX   PubMed=18408013; DOI=10.1074/jbc.M800756200;
RA   Gangabadage C.S., Zdunek J., Tessari M., Nilsson S., Olivecrona G.,
RA   Wijmenga S.S.;
RT   "Structure and dynamics of human apolipoprotein CIII.";
RL   J. Biol. Chem. 283:17416-17427(2008).
RN   [16]
RP   VARIANT C-III-0 ALA-94, AND GLYCOSYLATION AT THR-94.
RX   PubMed=3123586;
RA   Maeda H., Hashimoto R.K., Oguro T., Hiraga S., Uzawa H.;
RT   "Molecular cloning of a human apoC-III variant: Thr 74-->Ala 74
RT   mutation prevents O-glycosylation.";
RL   J. Lipid Res. 28:1405-1409(1987).
RN   [17]
RP   VARIANT HALP2 GLU-78.
RX   PubMed=2022742; DOI=10.1172/JCI115190;
RA   von Eckardstein A., Holz H., Sandkamp M., Weng W., Funke H.,
RA   Assmann G.;
RT   "Apolipoprotein C-III(Lys-58-->Glu). Identification of an
RT   apolipoprotein C-III variant in a family with
RT   hyperalphalipoproteinemia.";
RL   J. Clin. Invest. 87:1724-1731(1991).
CC   -!- FUNCTION: Component of triglyceride-rich very low density
CC       lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma
CC       (PubMed:18201179, PubMed:22510806). Plays a multifaceted role in
CC       triglyceride homeostasis (PubMed:18201179, PubMed:22510806).
CC       Intracellularly, promotes hepatic very low density lipoprotein 1
CC       (VLDL1) assembly and secretion; extracellularly, attenuates
CC       hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs)
CC       (PubMed:18201179, PubMed:22510806). Impairs the lipolysis of TRLs
CC       by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by
CC       remnant receptors (PubMed:18201179, PubMed:22510806). Formed of
CC       several curved helices connected via semiflexible hinges, so that
CC       it can wrap tightly around the curved micelle surface and easily
CC       adapt to the different diameters of its natural binding partners
CC       (PubMed:18408013). {ECO:0000269|PubMed:18408013,
CC       ECO:0000303|PubMed:18201179, ECO:0000303|PubMed:22510806}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000303|PubMed:18201179,
CC       ECO:0000303|PubMed:22510806}.
CC   -!- TISSUE SPECIFICITY: Liver. {ECO:0000269|PubMed:6328445}.
CC   -!- PTM: The most abundant glycoforms are characterized by an O-linked
CC       disaccharide galactose linked to N-acetylgalactosamine (Gal-
CC       GalNAc), further modified with up to 3 sialic acid residues. Less
CC       abundant glycoforms are characterized by more complex and
CC       fucosylated glycan moieties. O-glycosylated on Thr-94 with a core
CC       1 or possibly core 8 glycan. {ECO:0000269|PubMed:19838169,
CC       ECO:0000269|PubMed:23527852, ECO:0000269|PubMed:3123586}.
CC   -!- DISEASE: Hyperalphalipoproteinemia 2 (HALP2) [MIM:614028]: A
CC       condition characterized by high levels of high density lipoprotein
CC       (HDL) and increased HDL cholesterol levels.
CC       {ECO:0000269|PubMed:2022742}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the apolipoprotein C3 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J00098; AAB59515.1; -; Genomic_DNA.
DR   EMBL; M33043; AAB59372.1; -; Genomic_DNA.
DR   EMBL; M33041; AAB59372.1; JOINED; Genomic_DNA.
DR   EMBL; M33042; AAB59372.1; JOINED; Genomic_DNA.
DR   EMBL; X01392; CAA25648.1; -; Genomic_DNA.
DR   EMBL; X01388; CAA25644.1; -; mRNA.
DR   EMBL; X03120; CAA26895.1; -; Genomic_DNA.
DR   EMBL; V01513; CAA24757.1; -; mRNA.
DR   EMBL; M28613; AAA51760.1; -; mRNA.
DR   EMBL; M28614; AAA51761.1; -; mRNA.
DR   EMBL; X00567; CAA25233.1; -; mRNA.
DR   EMBL; AY422951; AAQ91810.1; -; Genomic_DNA.
DR   EMBL; AY555191; AAS68230.1; -; Genomic_DNA.
DR   EMBL; BC027977; AAH27977.1; -; mRNA.
DR   EMBL; BC121081; AAI21082.1; -; mRNA.
DR   CCDS; CCDS8377.1; -.
DR   PIR; A90950; LPHUC3.
DR   RefSeq; NP_000031.1; NM_000040.1.
DR   UniGene; Hs.73849; -.
DR   PDB; 2JQ3; NMR; -; A=21-99.
DR   PDBsum; 2JQ3; -.
DR   ProteinModelPortal; P02656; -.
DR   SMR; P02656; -.
DR   BioGrid; 106842; 5.
DR   IntAct; P02656; 3.
DR   MINT; MINT-5000873; -.
DR   STRING; 9606.ENSP00000227667; -.
DR   iPTMnet; P02656; -.
DR   PhosphoSitePlus; P02656; -.
DR   UniCarbKB; P02656; -.
DR   BioMuta; APOC3; -.
DR   DMDM; 114026; -.
DR   DOSAC-COBS-2DPAGE; P02656; -.
DR   SWISS-2DPAGE; P02656; -.
DR   EPD; P02656; -.
DR   MaxQB; P02656; -.
DR   PaxDb; P02656; -.
DR   PeptideAtlas; P02656; -.
DR   PRIDE; P02656; -.
DR   DNASU; 345; -.
DR   Ensembl; ENST00000227667; ENSP00000227667; ENSG00000110245.
DR   GeneID; 345; -.
DR   KEGG; hsa:345; -.
DR   UCSC; uc001ppt.2; human.
DR   CTD; 345; -.
DR   DisGeNET; 345; -.
DR   GeneCards; APOC3; -.
DR   HGNC; HGNC:610; APOC3.
DR   MalaCards; APOC3; -.
DR   MIM; 107720; gene.
DR   MIM; 614028; phenotype.
DR   neXtProt; NX_P02656; -.
DR   OpenTargets; ENSG00000110245; -.
DR   Orphanet; 79506; Cholesterol-ester transfer protein deficiency.
DR   Orphanet; 33271; Non-alcoholic fatty liver disease.
DR   PharmGKB; PA53; -.
DR   eggNOG; ENOG410JE3N; Eukaryota.
DR   eggNOG; ENOG4111APE; LUCA.
DR   GeneTree; ENSGT00390000015395; -.
DR   HOGENOM; HOG000247042; -.
DR   HOVERGEN; HBG050549; -.
DR   InParanoid; P02656; -.
DR   KO; K08759; -.
DR   PhylomeDB; P02656; -.
DR   TreeFam; TF338209; -.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SIGNOR; P02656; -.
DR   EvolutionaryTrace; P02656; -.
DR   GeneWiki; Apolipoprotein_C3; -.
DR   GenomeRNAi; 345; -.
DR   PRO; PR:P02656; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000110245; -.
DR   CleanEx; HS_APOC3; -.
DR   ExpressionAtlas; P02656; baseline and differential.
DR   Genevisible; P02656; HS.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034366; C:spherical high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0015485; F:cholesterol binding; IC:BHF-UCL.
DR   GO; GO:0030234; F:enzyme regulator activity; IDA:BHF-UCL.
DR   GO; GO:0070653; F:high-density lipoprotein particle receptor binding; IPI:BHF-UCL.
DR   GO; GO:0055102; F:lipase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:BHF-UCL.
DR   GO; GO:0034382; P:chylomicron remnant clearance; IDA:BHF-UCL.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IMP:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0060621; P:negative regulation of cholesterol import; IMP:BHF-UCL.
DR   GO; GO:0045717; P:negative regulation of fatty acid biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0010987; P:negative regulation of high-density lipoprotein particle clearance; IMP:BHF-UCL.
DR   GO; GO:0050995; P:negative regulation of lipid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0045833; P:negative regulation of lipid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0051005; P:negative regulation of lipoprotein lipase activity; IDA:BHF-UCL.
DR   GO; GO:0010989; P:negative regulation of low-density lipoprotein particle clearance; IMP:BHF-UCL.
DR   GO; GO:0048261; P:negative regulation of receptor-mediated endocytosis; IDA:BHF-UCL.
DR   GO; GO:0010897; P:negative regulation of triglyceride catabolic process; IDA:BHF-UCL.
DR   GO; GO:0010916; P:negative regulation of very-low-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0010903; P:negative regulation of very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0043691; P:reverse cholesterol transport; IC:BHF-UCL.
DR   GO; GO:0019433; P:triglyceride catabolic process; IDA:BHF-UCL.
DR   GO; GO:0070328; P:triglyceride homeostasis; IMP:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; IMP:HGNC.
DR   GO; GO:0034379; P:very-low-density lipoprotein particle assembly; TAS:BHF-UCL.
DR   InterPro; IPR008403; Apo-CIII.
DR   PANTHER; PTHR14225; PTHR14225; 1.
DR   Pfam; PF05778; Apo-CIII; 1.
DR   ProDom; PD010414; Apo-CIII; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chylomicron; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycoprotein;
KW   Lipid degradation; Lipid metabolism; Lipid transport; Polymorphism;
KW   Reference proteome; Secreted; Sialic acid; Signal; Transport; VLDL.
FT   SIGNAL        1     20       {ECO:0000269|PubMed:3949020,
FT                                ECO:0000269|PubMed:4846755}.
FT   CHAIN        21     99       Apolipoprotein C-III.
FT                                {ECO:0000269|PubMed:3949020}.
FT                                /FTId=PRO_0000002031.
FT   REGION       68     99       Lipid-binding.
FT   SITE         37     37       May interact with the LDL receptor.
FT                                {ECO:0000305|PubMed:18408013}.
FT   SITE         41     41       May interact with the LDL receptor.
FT                                {ECO:0000305|PubMed:18408013}.
FT   SITE         44     44       May interact with the LDL receptor.
FT                                {ECO:0000305|PubMed:18408013}.
FT   CARBOHYD     94     94       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:19838169,
FT                                ECO:0000269|PubMed:23527852,
FT                                ECO:0000269|PubMed:3123586}.
FT                                /FTId=CAR_000168.
FT   VARIANT      78     78       K -> E (in HALP2; dbSNP:rs121918382).
FT                                {ECO:0000269|PubMed:2022742}.
FT                                /FTId=VAR_000643.
FT   VARIANT      94     94       T -> A (in C-III-0; unglycosylated;
FT                                dbSNP:rs121918381).
FT                                {ECO:0000269|PubMed:3123586}.
FT                                /FTId=VAR_000644.
FT   CONFLICT     52     53       ES -> SQ (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     57     59       QQA -> AQQ (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        29     39       {ECO:0000244|PDB:2JQ3}.
FT   HELIX        40     42       {ECO:0000244|PDB:2JQ3}.
FT   HELIX        43     48       {ECO:0000244|PDB:2JQ3}.
FT   HELIX        49     55       {ECO:0000244|PDB:2JQ3}.
FT   HELIX        56     62       {ECO:0000244|PDB:2JQ3}.
FT   TURN         63     68       {ECO:0000244|PDB:2JQ3}.
FT   HELIX        69     80       {ECO:0000244|PDB:2JQ3}.
FT   HELIX        83     85       {ECO:0000244|PDB:2JQ3}.
FT   HELIX        93     98       {ECO:0000244|PDB:2JQ3}.
SQ   SEQUENCE   99 AA;  10852 MW;  D4E806339FAE4DA7 CRC64;
     MQPRVLLVVA LLALLASARA SEAEDASLLS FMQGYMKHAT KTAKDALSSV QESQVAQQAR
     GWVTDGFSSL KDYWSTVKDK FSEFWDLDPE VRPTSAVAA
//
